bostoncellstandards.com

What It Is

Boston Cell Standards (BCS) is not a typical horizontal SaaS product. It is a quality standardization platform for immunohistochemistry (IHC) cancer testing. Its core goal is to bring calibration, measurement traceability, quantitative quality control, and statistical process control (SPC)—concepts common in clinical chemistry—into IHC laboratories, reducing testing variation across different labs, instruments, and batches.

Core Features and Products

The platform consists of IHCalibrators, IHControls, image quantification software, and related consumables. IHCalibrators are used to calculate the limit of detection (LOD) and dynamic range, supporting alignment across laboratories, instruments, and clinical trial sites. IHControls are designed for routine SPC, generating Levey-Jennings charts, establishing control ranges, and tracking internal laboratory variation over time. The website also highlights use cases such as reagent lot-to-lot comparability verification, antibody dilution optimization, IHC troubleshooting, and clinical trial assay translation.

Pricing and Business Model

The website does not disclose public pricing, packages, or subscription tiers. It only provides entry points such as Order Now, Contact Us to Order, and Custom Solutions. As a result, procurement appears closer to a professional medical/life sciences product sales process than a self-service online SaaS subscription. For pharmaceutical companies and clinical trial use cases, BCS also offers custom calibration and SPC tool development.

Compliance and Credibility

According to the website, BCS is an ISO 13485-certified company. Some IHControls breast cancer panels are labeled IVD/RUO for the U.S. market and reference FDA 510(k) K220163. The company also discloses collaboration with NIST on reference standards and measurement traceability, and states that it has entered the final stage of the FDA MDDT program. These details are important for medical diagnostic quality scenarios, but use outside the U.S. still needs to be assessed against local regulatory requirements.

Pros, Cons, and Who It’s For

Its strengths are a clear positioning and a closed-loop capability around IHC accuracy, from reference materials to software reporting. It is especially suitable for pathology laboratories, IHC clinical testing institutions, pharmaceutical clinical trials, and companion diagnostics development teams. The limitations are that enterprise software details—such as deployment model, APIs, permissions, third-party integrations, and data security architecture—are barely disclosed. Pricing is not transparent, and some products are RUO or IVD only for the U.S. market.

Access from China and Alternatives

Information on access from mainland China, payment, and local delivery is not provided in the available text, so these remain unknown. For deployment in China, key issues to verify include import requirements, the boundary between registered and research-use products, cold chain or consumables supply, after-sales support, and local compliance. Alternatives typically include traditional IHC control materials, laboratory-built QC processes, or quality control systems provided by pathology equipment/reagent vendors.